Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025).
10.3760/cma.j.cn112138-20250707-00396
- Collective Name:Scientific Committee of the China IgA Nephropathy Network (IIgANN-China);Chinese Preventive Medicine Association′s Committee for the Prevention and Control of Kidney Diseases
- Publication Type:English Abstract
- MeSH:
Humans;
Glomerulonephritis, IGA/diagnosis*;
China;
Adult;
Vasculitis/complications*;
Practice Guidelines as Topic;
Immunoglobulin A;
Prognosis;
Nephritis/therapy*
- From:
Chinese Journal of Internal Medicine
2025;64(10):918-944
- CountryChina
- Language:Chinese
-
Abstract:
IgA nephropathy (IgAN) is the most common primary glomerular disease in China and a leading cause of end-stage renal disease (uremia) in young adults. The diagnosis, prognostic assessment, and treatment strategies for IgAN and IgA vasculitis with nephritis (IgAVN) have been comprehensively evaluated by the Scientific Committee of the China IgA Nephropathy Network (IIgANN-China) and the Chinese Preventive Medicine Association's Committee for the Prevention and Control of Kidney Diseases based on recent literature and evidence-based medicine. As a result, clinical practice guidelines specifically tailored to Chinese patients have been developed. These guidelines introduce an integrated therapeutic framework that incorporates risk-stratified treatment, targeting both immune-mediated renal injury and chronic kidney disease progression, as well as stage-specific treatment, including both the induction and maintenance phases. The aim is to provide standardized guidance and practical recommendations for the clinical management of IgAN and IgAVN in China.
